Molecular Partners AG: Thursday, 04 February 2016, 2:00pm (CET) – Presentation for media, analysts and investors Donnerstag, 21. Januar 2016 - 18:32

Thursday, 04 February 2016, 2:00pm (CET) – Presentation for media, analysts and investors

Dear Sir/Madam

Molecular Partners AG cordially invites you to participate in the presentation of the company’s full-year results 2015 which will take place as follows:

Date:	Thursday, 04 February 2016
Time:	2:00pm CET (1:00pm GMT, 8:00am EST)
Location:	SIX Convention Point, Auditorium, Selnaustrasse 30, 8001 Zurich

Please indicate if you would like to attend the presentation by completing and returning theregistration form by Monday, 01 February 2016.
Telephone dial-in facilities and an audio webcast will be available for those who are unable to attend the event.

The 2015 earnings releaseand additional information will be available onwww.molecularpartners.com from 7:00am (CET) on Thursday, 04 February 2016.
The full Annual Report 2015 of the company will be published on 17 March 2016.

Best regards,
Investor Relations

Molecular Partners AG

Dial-ins for the conference call:
Switzerland / Europe	+41 (0) 58 310 5000
UK	+44 (0) 203 059 5862
USA	+1 (1) 631 570 5613

Please dial-in approximately 10 minutes before the start of the presentation in order to register. Participants will have the opportunity to ask questions after the presentation.

To follow the audio webcast of the presentation:
The audio webcast will be accessible, both live and as a replay, on www.molecularpartners.com, along with the accompanying presentation slides.
To follow the presentation live, you will need to log in and register prior to the event.

Investor distribution list:
If you wish to be removed from the distribution list, please email us atinvestors@molecularpartners.com.

About Molecular Partners AG

Molecular Partners is a clinical-stage biopharmaceutical company that is developing a new, powerful class of therapies known as DARPins. DARPins are potent, specific, and versatile small-protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. The DARPin technology has the potential to offer a multi-specific approach to treatment, which enables DARPins to target multiple pathways, or multiple epitopes on a single target to achieve substantial patient benefit. DARPins have the potential to advance modern medicine and significantly improve the treatment of serious diseases, including cancer and sight-threatening disorders.

Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in the research stage, with a current focus on ophthalmology and oncology. The company has ongoing research and development partnerships with leading pharmaceutical companies, including Allergan and Janssen, and is backed by established biotech investors.

For more information regarding Molecular Partners go to: www.molecularpartners.com.